Login    Join free Add to favorites    中文
home > news > EKF Diagnostics Launched the Quo-Lab® point-of-care HbA1c Analyzer
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
EKF Diagnostics Launched the Quo-Lab® point-of-care HbA1c Analyzer

hits:507     Date:07/20/18
EKF POC HbA1c analyzer demonstrates excellent performance in international evaluation study
 
Quo-Lab meets strict international quality targets 鈥 confirming it fit for purpose for diabetes testing

EKF鈥檚 Quo-Lab POC HbA1c analyzer meets all international quality targets for diabetes testing
 (For a high resolution image, please contact sarahp@alto-marketing.com)
        
Cardiff, UK 鈥 19 July 2018 鈥 EKF Diagnostics, the global in vitro diagnostics company, has announced the successful evaluation of its Quo-Lab® point-of-care HbA1c analyzer by the European Reference Laboratory for Glycohemoglobin. In a recently published paper [1], the reference laboratory鈥檚 evaluation study assessed HbA1c (glycated hemoglobin) POC devices using international quality targets, posing the question 鈥楢re they fit for purpose?鈥 Out of 30 available on the market and the four that agreed to participate, only EKF鈥檚 Quo-Lab and one other analyzer passed the same stringent quality criteria as laboratory analyzers, achieving excellent analytical performance.
 
The study aimed to evaluate the four POC HbA1c instruments according to Clinical and Laboratory Standards Institute (CLSI) protocols and how they performed when different criteria were applied using four certified IFCC and NGSP secondary reference measurement procedures (SRMPs). The reference laboratory study confirmed there was minimal bias between Quo-Lab and the mean of four SRMPs, it also passed all relevant performance criteria going far beyond what is required for NGSP and IFCC certification.
 
Notably, Quo-Lab showed no consistent clinically significant interference from the common hemoglobin (Hb) variants HbAS, HbAC, HbAD, HBAE and elevated A2. It also easily met imprecision criteria, achieving a 鈮2.4% CV in IFCC SI units and 鈮1.7% CV in DCCT units which represents a significant improvement on previous studies.
 
This evaluation success follows last year鈥檚 similarly excellent evaluation of EKF鈥檚 Quo-Test® HbA1c analyzer which was again confirmed to meet IFCC performance criteria [2]. Although not included in this latest study, Lenters-Westra felt it important enough to mention in the conclusion that the Quo-Test鈥檚 improved performance also had no bias compared to the mean of three SRMPs [1].
 
Commenting on the successful European Reference Laboratory for Glycohemoglobin evaluation, Gavin Jones, Diabetes Product Manager, EKF Diagnostics said, 鈥淭he excellent performance that Quo-Lab has demonstrated in this latest study confirms that it is very definitely fit for purpose, delivering reliable HbA1c results in a range of settings. This study also highlights the performance improvements that we have made to both our Quo-Lab and Quo-Test HbA1c analyzers to fulfill increasingly tough requirements from the IFCC. This means that both analyzers meet the same rigorous quality criteria as laboratory analyzers.鈥
 
Quo-Lab® HbA1c is a desktop analyzer designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand low cost of operation and ease of use. From a simple semi-automated procedure, Quo-Lab provides test results within four minutes from a venous or finger prick blood sample of just 4 渭L. Quo-Lab uses the same boronate affinity methodology as Quo-Test which is also unaffected by Hb variants. Step-by-step instructions are displayed on a clear, multi-lingual display, therefore, staff training time is minimized and opportunity for error reduced. Quo-Lab is CE marked and available for sale in most global markets subject to local registration requirements.
 
For full information on the EKF Diagnostics Group, please visit www.ekfdiagnostics.com
 
References:
1) Lenters-Westra, E. & English, E. Evaluation of four HbA1c point-of-care devices using international quality targets: Are they fit for purpose? J Diabetes Sci Technol. 2018 Jul;12(4):762-770.  
 
About EKF Diagnostics - www.ekfdiagnostics.com or www.ekfusa.com  
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, Stanbio Laboratory and DiaSpect brands, specializes in the development, production and worldwide distribution of point-of-care analyzers for use in the detection and management of diabetes and anemia, and also in sports and maternal medicine. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.
 
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
 
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents, as well as associated analyzers. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙